US Markets

Moderna says discussing supply deals with countries for COVID-19 vaccine

Credit: REUTERS/Brian Snyder

Moderna Inc is in talks with several countries for supply agreements for its experimental coronavirus vaccine, the company said on Wednesday, adding that it had already received about $400 million in deposits for potential supply.

Adds background, changes media packaging code

Aug 5(Reuters) - Moderna Inc MRNA.O is in talks with several countries for supply agreements for its experimental coronavirus vaccine, the company said on Wednesday, adding that it had already received about $400 million in deposits for potential supply.

The company's vaccine candidate is one of the few to be in the final stages of testing as drugmakers race to develop a safe and effective vaccine against the pandemic that has claimed more than 700,000 lives worldwide.

Last week, Moderna announced the start of a late-stage trial on 30,000 people to demonstrate that its vaccine was safe and effective, the final hurdle prior to regulatory approval. It has said the vaccine could be ready for widespread use by the end of this year.

The company, which ended the quarter with $3.1 billion in cash, cash equivalents and investments, said it was on track to complete enrollment in the study in September.

Moderna said last month it plans to price its coronavirus vaccine in a way that ensures broad access and that it did not intend to conduct late-stage trials of the vaccine outside the United States.

"As we pivot to a commercial stage company, we recognize the need for responsible pricing in the face of the pandemic," Chief Executive Officer Stéphane Bancel said in a statement.

The company, which has no drug on the market, has received nearly $1 billion from the U.S. government under a plan to speed up vaccine development.

FACTBOX-U.S. pours billions into securing access to coronavirus vaccine candidates

FACTBOX- The race for a coronavirus vaccine

UPDATE 5-Moderna COVID-19 vaccine could be ready for use by end of year, U.S. says

INSIGHT-How Moderna execs are cashing in on COVID-19 vaccine stock speculation

(Reporting by Ankur Banerjee in Bengaluru; Editing by Saumyadeb Chakrabarty)

((ankur.banerjee@thomsonreuters.com;; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132; Twitter: @AnkurBanerjee17;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRNA

Other Topics

World Markets

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More